"Diabetic Nephropathies" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.
| Descriptor ID |
D003928
|
| MeSH Number(s) |
C12.777.419.192 C13.351.968.419.192 C19.246.099.875
|
| Concept/Terms |
Diabetic Nephropathies- Diabetic Nephropathies
- Nephropathies, Diabetic
- Nephropathy, Diabetic
- Diabetic Nephropathy
- Diabetic Kidney Disease
- Diabetic Kidney Diseases
- Kidney Disease, Diabetic
- Kidney Diseases, Diabetic
Diabetic Glomerulosclerosis- Diabetic Glomerulosclerosis
- Kimmelstiel-Wilson Syndrome
- Kimmelstiel Wilson Syndrome
- Syndrome, Kimmelstiel-Wilson
- Kimmelstiel-Wilson Disease
- Kimmelstiel Wilson Disease
- Nodular Glomerulosclerosis
- Glomerulosclerosis, Nodular
- Glomerulosclerosis, Diabetic
- Intracapillary Glomerulosclerosis
|
Below are MeSH descriptors whose meaning is more general than "Diabetic Nephropathies".
Below are MeSH descriptors whose meaning is more specific than "Diabetic Nephropathies".
This graph shows the total number of publications written about "Diabetic Nephropathies" by people in this website by year, and whether "Diabetic Nephropathies" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 3 | 3 |
| 1996 | 1 | 0 | 1 |
| 1997 | 2 | 2 | 4 |
| 1999 | 0 | 1 | 1 |
| 2000 | 2 | 1 | 3 |
| 2003 | 2 | 1 | 3 |
| 2004 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 2 | 1 | 3 |
| 2007 | 3 | 1 | 4 |
| 2008 | 4 | 1 | 5 |
| 2009 | 1 | 4 | 5 |
| 2010 | 5 | 2 | 7 |
| 2011 | 2 | 3 | 5 |
| 2012 | 2 | 0 | 2 |
| 2014 | 0 | 2 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 1 | 2 |
| 2019 | 2 | 1 | 3 |
| 2020 | 1 | 0 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Diabetic Nephropathies" by people in Profiles.
-
Rilparencel (Renal Autologous Cell Therapy-REACT®) for Chronic Kidney Disease and Type 1 and Type 2 Diabetes: Phase 2 Trial Design Evaluating Bilateral Kidney Dosing and Redosing Triggers. Am J Nephrol. 2024; 55(3):389-398.
-
Genetic drivers of heterogeneity in type 2 diabetes pathophysiology. Nature. 2024 Mar; 627(8003):347-357.
-
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis. Ann Intern Med. 2023 12; 176(12):1606-1616.
-
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria. Circulation. 2024 02 06; 149(6):450-462.
-
Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression. Diabetes Care. 2023 09 01; 46(9):1574-1586.
-
Slowing the Progression of Diabetic Kidney Disease. Cells. 2023 07 31; 12(15).
-
Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis. Clin J Am Soc Nephrol. 2023 05 01; 18(5):602-612.
-
Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE). Nephrol Dial Transplant. 2023 03 31; 38(4):894-903.
-
Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial. Am J Kidney Dis. 2023 07; 82(1):84-96.e1.
-
Effects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baseline. Diabetes Obes Metab. 2023 06; 25(6):1512-1522.